Dr Christine Wilkinson Blanc appointed as Chief Medical Officer at Nordic Nanovector

pharmafile | August 10, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Nordic Nanovector has announced that Dr Christine Wilkinson Blanc has been appointed as the Chief Medical Officer of the company.

Blanc has over 25 years of experience in the pharmaceutical industry and has joined the company through her relationship with Weatherden, a specialist clinical development consulting and execution company. She has been the Medical Director at Phi-Medics for 10 years supporting clients like Roche, Pierre Fabre, Innate Pharma, IPSEN and Antisome. She was also the Chief Medical Officer of Psioxus Therapeutics between 2013 and 2016. Prior to this, Wilkinson Blanc was Medical Director in Oncology for companies like Roche, Aventis, Ariad Pharma and GE Healthcare.

Lars Nieba, Interim Chief Executive Officer, commented on Blanc’s appointment: “I would like to thank Dominic his dedication and valuable contributions to the advancement of the Company. I am very pleased that Christine has joined Nordic Nanovector as CMO. Her vast experience in clinical development, particularly in oncology and haematology, will be invaluable as we focus our resources and energy on completing the PARADIGME study.”

Dr Wilkinson Blanc received her medical qualification and specialisation in Medical Biology at the Universities of Medicine of Lille and Lyon, France.

Dr Wilkinson Blanc also spoke on her appointment: “I am excited to be joining Nordic Nanovector as it works to ensure the completion of PARADIGME in a timely fashion. Betalutin® is an exciting one-time treatment which has shown very promising efficacy data in advanced follicular lymphoma. With a clear development path following the recent successful Interim Analysis, I am looking forward to making an important contribution to bring this novel drug candidate to this fragile patient population, which is clearly in need of much improved treatment options.”

Related Content

No items found

Latest content